Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.
Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.
Methotrexate was granted FDA approval on 7 December 1953.
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00070174
- Locations
- 🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸All Children's Hospital, St. Petersburg, Florida, United States
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 121
- Registration Number
- NCT00070135
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇺🇸Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 60
- Registration Number
- NCT00068250
- Locations
- 🇺🇸
Providence Milwaukie Hospital, Milwaukie, Oregon, United States
🇺🇸Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸Flagler Cancer Center, Saint Augustine, Florida, United States
506U78 in Treating Patients With Refractory Hematologic Cancer
- First Posted Date
- 2003-08-11
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00002970
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- Radiation: iodine I 131 monoclonal antibody BC8Drug: busulfanDrug: cyclophosphamideProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationDrug: cyclosporineDrug: methotrexateOther: laboratory biomarker analysis
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00005940
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Pacific Northwest National Laboratory, Richland, Washington, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
- Conditions
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 6000
- Registration Number
- NCT00002582
- Locations
- 🇬🇧
Cancer Research Campaign Trials Unit-Birmingham (CRCTU), Birmingham, England, United Kingdom
🇬🇧Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
- Conditions
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2010-05-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00025545
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇪🇬National Cancer Institute of Egypt, Cairo, Egypt
🇮🇳Kidwai Memorial Institute of Oncology, Bangalore, India
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Acute Undifferentiated LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaL1 Adult Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaL2 Adult Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
- Interventions
- Drug: allopurinolDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: vincristine sulfateDrug: dexamethasoneDrug: asparaginaseBiological: filgrastimDrug: imatinib mesylateDrug: methotrexateDrug: cytarabineDrug: trimethoprim-sulfamethoxazoleDrug: mercaptopurineDrug: leucovorin calciumBiological: alemtuzumabDrug: acyclovirOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 302
- Registration Number
- NCT00061945
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
- First Posted Date
- 2003-05-21
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 83
- Registration Number
- NCT00005977
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Texas Oncology P.A., Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.